Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C

Transplantation

Volumn 81, Issue 12, 2006, Pages 1747-1749

  Taniguchi, Masahiko ^a   Furukawa, Hiroyuki ^a   Shimamura, Tsuyoshi ^a   Suzuki, Tomomi ^a   Yamashita, Kenichiro ^a   Ota, Minoru ^a   Todo, Satoru ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DFPP; HCV; Interferon; Living donor liver transplantation; Prophylaxis

Indexed keywords

BASILIXIMAB; BETA INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA;

ADULT; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; DEPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; VIREMIA;

DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON TYPE I; LIVER TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; PILOT PROJECTS; PLASMAPHERESIS; RIBAVIRIN; RNA, VIRAL;

EID: 33745467105     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226075.04938.43     Document Type: Article

References (15)

1. Fukumoto T, Berg T, Ku Y, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24(6): 1351.
2. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32(5): 1125.
3. Davis SE, Portmann BC, O'Grady IG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13(1): 150.
4. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23(5): 971.
5. Troppmann C, Rossaro L, Perez RV, McVicar IP. Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation. Am J Transplant 2003; 3(2): 239.
6. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9(10): 1028.
7. Aiyama T, Yoshioka K, Takayanagi M, et al. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatol 1995; 23(5): 497.
8. Jensen DM, Krawitt EL, Keeffe EB, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999; 94(12): 3583.
9. Yeh JH, Chiu HC. Double filtration plasmapheresis in myasthenia gravis - analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand 1999; 100(5): 305.
10. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993; 67(4): 1953.
11. Kaito M, Watanabe S, Tsukiyama-Kohara K, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994; 75: 1755.
12. Sakai A, Kaneko S, Kobayashi K. Immunoadsorption therapy for HCV infected chimpanzee. Nippon Rinsho 2001; 59(7): 1374.
13. Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis. Transfusion 2004; 44(11): 1621.
14. Yeh JH, Chiu HC. Coagulation abnormalities in serial double-filtration plasmapheresis. J Clin Apheresis 2001; 16(3): 139.
15. Lin SM, Yeh JH, Lee CC, Chiu HC. Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis. J Clin Apheresis 2003; 18(2): 67.